Revista de Hematología

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Revista de Hematología >Year 2012, Issue 2

Gómez-Almaguer D, Flores-Jiménez JA, Cantú-Rodríguez O, Gutiérrez-Aguirre CH
Advantages of Hematopoietic Cells Transplant in Cases of Acute Myeloid Leukaemia
Rev Hematol Mex 2012; 13 (2)

Language: Español
References: 33
Page: 74-79
PDF: 82.26 Kb.

Full text


Hematopoietic stem cell transplantation in its various forms has been used as a treatment for acute myeloid leukemia principally as rescue in relapsed leukemia. Today different cytogenetic and molecular markers have allowed guide treatment for each patient in a more individualized manner. In this way it is possible to assess the risk and thus the prognosis of the patient. The long-term survival remains a challenge for clinicians with not very encouraging numbers for developing countries. The addition of medications such as all-trans retinoic acid to chemotherapy regimens has demonstrated an excellent response and cure rates in promyelocytic leukemia. The combination of cytotoxicity and graft versus leukemia effect has allowed hematopoietic stem cell transplantation to be considered as an important therapeutic resource always guided by variables such as age, clinical condition, risk group ant matched donor availability.

Key words: acute myeloid leukemia, hematopoietic stem cell transplantation, citogenetics.


  1. Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica 2008;93(4):594-600.

  2. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368(9550):1894-907.

  3. Drexler HG. Classification of acute myeloid leukemias-a comparison of FAB and immunophenotyping. Leukemia 1987;1(10):697-705.

  4. Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood 2004;103(11):4036-42.

  5. Olesen LH, Aggerholm A, Andersen BL, Nyvold CG, Guldberg P, Norgaard JM, et al. Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling. Br J Haematol 2005;131(4):457-67.

  6. Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer. 2001;92(5):1059-73.

  7. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312-1320.

  8. Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011;117(8):2307-2318.

  9. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94(10):3315-3324.

  10. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006;107(7):2627-2632.

  11. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107(9):3469-3473.

  12. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxidebased therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009;106(9):3342-3347.

  13. Arlin Z, Case DC, Jr, Moore J, Wiernik P, Feldman E, Saletan S, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 1990;4(3):177-183.

  14. MacCallum PK, Davis CL, Rohatiner AZ, Lim J, Gupta RK, Whelan JS, et al. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence. Leukemia 1993;7(10):1496-1499.

  15. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58(18):4173-4179.

  16. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 2011;117(8):2358-2365.

  17. Lobato-Mendizabal E, Ruiz-Arguelles GJ, Gomez-Almaguer D, Ganci-Cerrud G, Lozano de la Vega A, Labardini- Mendez J. [Long-term treatment and prognostic factors in adult acute myeloblastic leukemia. Experience of the INNSZ group Puebla-Monterrey-Mexico)]. Rev Invest Clin 1991;43(3):215-222.

  18. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005;103(8):1652-1658.

  19. Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011;118(23):6037-6042.

  20. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112(12):4371-4383.

  21. Gutierrez-Aguirre CH, Cantu-Rodriguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-Gonzalez O, Jaime-Perez JC, et al. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology 2007;12(3):193-197.

  22. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reducedintensity conditioning: the role of dose intensity. Leukemia 2006;20(2):322-328.

  23. Ruiz-Arguelles GJ, Gomez-Almaguer D, David-Gomez-Rangel J, Vela-Ojeda J, Cantu-Rodriguez OG, Jaime-Perez JC, et al. Allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: a prospective study. Leuk Lymphoma 2004;45(6):1191-1195.

  24. Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D, et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005;19(6):916-920.

  25. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447-3454.

  26. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104(3):865-872.

  27. Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ, et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005;104(9):1931-1938.

  28. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23(24):5728-5738.

  29. Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL, et al. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant 2007;13(5):560-567.

  30. Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, et al. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica 2007;92(3):389-396.

  31. de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica 2010;95(10):1754-1761.

  32. Martins C, Lacerda JF, Lourenco F, Carmo JA, Lacerda JM. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience. Acta Med Port 2005;18(5):329-337

  33. Reisner Y, Hagin D, Martelli M. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood. 2011;118 (23):6006-6017.

>Journals >Revista de Hematología >Year 2012, Issue 2

· Journal Index 
· Links 

Copyright 2019